$$ D E T O N A T I O N $$

www.marketwatch.com/news/story/...26353%7D&dist=TQP_Mod_pressN

BOCA RATON, Fla., Oct 2, 2007 (PrimeNewswire via COMTEX) -- Genesis Technology Group, Inc. (GTEC:genesis technology group inc com
News, chart, profile, more
Last: 0.20+0.10+90.48%

9:51am 10/02/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

GTEC 0.20, +0.10, +90.5%) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.
Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.
Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.
Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: "Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.
"It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.

bei 0,28

"It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.

"The details of the merger will be explained fully in filings with the Securities & Exchange Commission and in a letter to be posted on our website www.Genesis-China.net," explained Mr. Wolfson.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that partners with qualified Chinese companies to expand their domestic and international market opportunities. The customized private-to-public program seeks to tap in to Western capital markets to attain this goal. Commitment, dedication, and expertise are the key components to the Genesis "Mission Statement." It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined "partner companies." Genesis makes a long-term commitment with management consultation, board of directors' composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners' leadership potential in China and attempts to increase high-margin, predictable earnings. The forgoing description is prior to completion of the merger, which has resulted in Genesis Pharmaceutical Enterprises, Inc., the name of the merged company. For more information, visit www.Genesis-China.net.

Safe Harbor Statement and Disclaimer

Certain statements set forth in this press release constitute "forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. The capital and growth program, the Company's central profit center, has specific risks and liabilities. Followers of our business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While receipt of a significant equity position in these companies is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables.

CONTACT:  Genesis Pharmaceutical Enterprises, Inc.
         Elsa Sung, Chief Financial Officer
         (800) 867-0078, ext. 602
         Fax: (561) 988-9890
         info@Genesis-China.net
         7900 Glades Road, Suite 420
         Boca Raton, Florida 33434



Source: PrimeNewswire (October 2, 2007 - 8:34 AM EST)

News by QuoteMedia
www.quotemedia.com  

zu 0,21 in FFm und Stuttgart

Hallo,
ich lese im folgenden Forum öfters was über ein Ziel von 5 Dollar.
Desweiteren stehen da Fälle von Aktien, mit denen ähnliches passiert ist und welche dann z.B. von 0,02 auf 11,00 gestiegen sind.

investorshub.advfn.com/boards/board.asp?board_id=743

gruß

ganz aktuell vom CEO :


www.genesis-china.net

Profile of LJPC

For its fiscal year ended June 30, 2007, LJPC reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000. Revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period, based on research by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City in September.

LJPC's fiscal years, as audited by MSWFT, run from July 1st to June 30th of each calendar year. Moore Stephens will serve as GTEC's auditor going forward.

An independent U.S. financial advisor accompanied Dr. Tan and Mr. Wolfson to LJPC last month and provided the following information:

   *

     Laiyang Jiangbo Pharmaceuticals was established in July 2003 and is a medium-sized pharmaceutical company that is currently producing and selling five (5) Government approved drugs with several in the pipeline awaiting final approval. The company is located in Northeast China in an Economic Development Zone, Laiyang City, Shandong Province.
   *

     The company has 440 full time sales representatives and 620 part time representatives located in all major commerce areas across China
   *

     The company has numerous GMP (Chinese State Drug Administration - SDA) approved manufacturing facilities and production lines and is approved to produce tablets, capsules and granules. In 2007, LJPC produced 300 million tablets, 50 million bags of granule and 50 million capsules. Company's top four products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Ciprofloxacin Hydrochloride tablets, and Paracetamol tablets.  

To call the merger the "crowning achievement" of management is no exaggeration.

What is the Valuation of Genesis Pharmaceutica Enterprises, Inc?

GTEC has just announced a reverse merger of a profitable Chinese company that earned $22 Million in the last 12 months...and has $17 million cash in the bank. I don't know exactly what numbers you multiply to calculate a companies value...but surely any company must be worth 15-20 times its annual net income. If we do that, we get the following totals:

$22 million times 15 ='s a valuation of $330,000,000
$22 million times 20 ='s a valuation of $440,000,000
$22 Million times 30 ='s a valuation of $660,000,000

On a per share basis that would give us between .83, $1.10 and $1.65 per share.

That's waaaay higher than current share price.....

PLUS GTEC's prior assets will be distributed to GTEC shareholders. Their book value was $7.6 million in last 10Q. With 100,000,000 shares to distribute the assets to, that comes out to 76 cents per share. NOTICE, the valuations they used were minimal not even current market prices. Current market price would put the value of this distribution at buck or two. Scary good.

I think GTEC will see $3-5.00 probably much more before all is done.

PLUS we have a growing profitable pharmeceutical company.

I just can't see selling too many of my shares until this distribution is made.  

GTEC- from previous reverse mergers that GTEC falls into the same category,
shellstockreview,
how about a Shell Stock that went from $0.10 to $11.20 in two days, and later traded as high as $30
But after completing a Reverse Merger, they can explode in price and increase in value by 10 times, 20 times, and possibly over 100 times their original share price!

GTEC-merger company (LJPC) is believed to be only the second Chinese company in the country to obtain CRSC Regulation No. 106 approval from the
government, which officially permits the completion of such a merger with a U.S. public company.

GTEC- Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("LJPC"),For its fiscal year ended June 30, 2007, LJPC reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000. Revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period, based on research by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City in early September.

Das eine Aktie, wo ähnliches passiert ist innerhalb von 2 Tagen von 0,1 auf 11,10 gestiegen ist und dann weiter auf 30,00. Und sich Genesis nach dieser Rückfusion ver-100-fachen könnte....

Dich zwingt ja auch keiner ,ich dgegen bin froh dass ich welche hab((--;

Ich denke das nächste Ziel liegt hete Nachmittag bei 0,30Euro.

Und außer dem gab es in der Vergangenheit viele Werte die als Dreck betitelt wurden

die einige heute gern in ihrem Depot hätten.

Gruß

Es geht gleich los

Realtime-Kursabfrage
Bitte beachten Sie, dass es sich bei den angezeigten Kursen nicht um Realtime-Kurse handelt.

                                                                                §
          § WKN / ISIN 931506  /  US37184Q1022  

          § Wertpapierbezeichnung GENESIS TECHNOLOGY GROUP INC.REG.SHS  

          § Handelsplatz

Kursdaten (in  EUR), Stand:  14:59 Uhr 03.10.2007 Volumen

Letzter Kurs 0,26 k.A.
Geld 0,25 10.000  St.
Brief 0,27 20.000  St.